Multiple myeloma is a heterogenous disease with variability in the presentation of its cytogenetic, molecular and proliferative features. But the treatment of multiple myeloma, particularly in relapsed disease is even more complex. With a therapeutic landscape that has recently exploded with new agents and label extensions and no one standard treatment, clinicians and patients continue ...
Are we there yet? The long road to cure in relapsed multiple myeloma
By Catherine Panwar
9 Feb 2017
Sponsored by Celgene Pty Ltd